

EBLE, Johannes A., Prof. Dr. rer. nat.**Contact**

Institut für Physiologische Chemie und Pathobiochemie,
Westfälische Wilhelms-Universität
Waldeyerstr. 15, 48149 Münster, Deutschland

Phone: 0251-8355591; E-Mail: johannes.eble@uni-muenster.de

**Personal Details**

Date of birth: 26.04.1964, W3 professor, Head of Institut für Physiologische Chemie

Education

1984-1991 Diploma in Biochemistry, Universität Tübingen

Academic Degrees

2004 Habilitation, Physiological Chemistry and Pathobiochemistry, Westfälische Wilhelms-Universität Münster, Prof. Dr. P. Bruckner
1994 Promotion, Biochemistry, Max Planck-Institut für Biochemie, Ludwig Maximilians-Universität München, Prof. Dr. K. Kühn

Employment History

2014 - Director, Institut für Physiologische Chemie, Westfälische Wilhelms-Universität Münster
2008 - 2013 Head of Dept. Vascular Matrix Biology, Excellence Cluster Cardio-Pulmonary System, Goethe Universität Frankfurt
2004 - 2007 Independent group leader, Institut für Physiologische Chemie und Pathobiochemie, Westfälische Wilhelms-Universität Münster
1998 - 2003 Research assistant, Institut für Physiologische Chemie und Pathobiochemie, Westfälische Wilhelms-Universität Münster
1995 - 1998 Postdoctoral fellow, Dana Faber-Cancer Institute, Harvard Medical School, Boston, USA; Prof. Dr. M. Hemler's group
1994 - 1995 Postdoctoral fellow, Max Planck-Institut für Biochemie, Munich; Prof. Dr. K. Kühn's group

Additional Information**Memberships**

2014 - Member of Excellence Cluster Cell-in-Motion (CiM), Westfälische Wilhelms-Universität Münster
2013 - 2016 Member of the European Marie Curie-Initial Training Network CAFFEIN
2008 - 2013 Member of the Excellence Cluster Cardio-Pulmonary System, Goethe Universität Frankfurt
2008 - 2016 Secretary and Board Member of the German Society for Matrix Biology
2008 - Member of the International Scientific Advisory Board of the International Institute for Anticancer Research (IIAR)
2007 - 2016 Member of the COST Actions, D39 and CM1105
2006 - 2011 Member of the Editorial Board of MATRIX BIOLOGY

Awards/Honours

- 2004 Technology Transfer Prize 2003 of the Westfälische Wilhelms-Universität Münster
- 1995 – 1997 Research Fellowship of DFG
- 1995 Otto Hahn-Medal, including fellowship, of the Max Planck Society

Most Important Publications

Peer-reviewed Journals and Books

- (1) Eble JA, de Rezende FF. Redox-relevant aspects of the extracellular matrix and its cellular contacts via integrins. **Antioxid Redox Signal** 20: 1977-1993 (2014)
- (2) Niland S, Ditkowski B, Parrandier D, Roth L, Augustin H, Eble JA. Rhodocetin-alphabeta-induced neuropilin-1-cMet association triggers restructuring of matrix contacts in endothelial cells. **Arterioscler Thromb Vasc Biol** 33: 544-554 (2013)
- (3) Arlinghaus FT, Eble JA. C-type lectin-like proteins from snake venoms. **Toxicon** 60: 512-519 (2012)
- (4) Niland S, Westerhausen C, Schneider SW, Eckes B, Schneider MF, Eble JA. Biofunctionalization of a generic collagenous triple helix with the $\alpha 2\beta 1$ integrin binding site allows molecular force measurements. **Int J Biochem Cell Biol** 43: 721-731 (2011)
- (5) Eble JA, Niland S, Bracht T, Mormann M, Peter-Katalinic J, Pohlentz G, Stetefeld J. The $\alpha 2\beta 1$ integrin-specific antagonist rhodocetin is a cruciform, heterotetrameric molecule. **FASEB J** 23: 2917-2927 (2009)
- (6) de Santana Evangelista K, Andrich F, Figueiredo de Rezende F, Niland S, Cordeiro MN, Horlacher T, Castelli R, Schmidt-Hederich A, Seeberger PH, Sanchez EF, Richardson M, Gomes de Figueiredo S, Eble JA. Plumieribetin, a fish lectin homologous to mannose-binding B-type lectins, inhibits the collagen-binding $\alpha 1\beta 1$ integrin. **J Biol Chem** 284: 34747-34759 (2009)
- (7) Navdaev A, Heitmann V, Desantana Evangelista K, Mörgelin M, Wegener J, Eble JA. The C-terminus of the $\gamma 2$ chain but not of the $\beta 3$ chain of laminin-332 is indirectly but indispensably necessary for integrin-mediated cell reactions. **Exp Cell Res** 314: 489-497 (2008)
- (8) Eble JA, Bruckner P, Mayer U. Vipera lebetina venom contains two disintegrins inhibiting laminin-binding $\beta 1$ integrins. **J Biol Chem** 278: 26488-26496 (2003)
- (9) Eble JA, Wucherpfennig KW, Gauthier L, Dersch P, Krukonis E, Isberg RR, Hemler ME. Recombinant soluble human $\alpha 3\beta 1$ integrin: purification, processing, regulation, and specific binding to laminin-5 and invasin in a mutually exclusive manner. **Biochemistry** 37: 10945-10955 (1998)
- (10) Eble JA, Golbik R, Mann K, Kuhn K. The $\alpha 1\beta 1$ integrin recognition site of the basement membrane collagen molecule $[\alpha 1(IV)]_2 \alpha 2(IV)$. **EMBO J** 12: 4795-4802 (1993)

Filed Patents

- (1) Lazarovici P, Momic T, Katzhendler J, Eble JA, Arien-Zakay H. Viperastatin-derived peptides and uses thereof. U.S. Provisional Patent Application, No. 61/916,231 (2014)